Journal of Child and Adolescent Psychopharmacology · 2016 · 103 citations · 21 references
MedicinePharmacologyPharmacotherapyAutism Spectrum DisordersNeuropharmacologyPsychopharmacologyChild PsychopharmacologyGlutamatergic PharmacologyNeurodevelopmental DisordersNeuropsychiatric PharmacotherapyPediatric PsychopharmacologyPsychopharmacology In ChildrenGlutamatergic NeurotransmissionN-methyl-d-aspartate Receptor AntagonismN-methyl-d-aspartate Receptor InhibitionNmda Receptor AntagonistsNmda Receptor PharmacologyPediatric Stimulant MedicationsPediatric Trial DesignPlacebo-controlled Efficacy Assessment
OBJECTIVE: Abnormal glutamatergic neurotransmission is implicated in the pathophysiology of autism spectrum disorder (ASD). In this study, the safety, tolerability, and efficacy of the glutamatergic N-methyl-d-aspartate (NMDA) receptor antagonist memantine (once-daily extended-release [ER]) were investigated in children with autism in a randomized, placebo-controlled, 12 week trial and a 48 week open-label extension. METHODS: A total of 121 children 6-12 years of age with Diagnostic and Statistical Manual of Mental Disorders, 4th ed., Text Revision (DSM-IV-TR)-defined autistic disorder were randomized (1:1) to placebo or memantine ER for 12 weeks; 104 children entered the subsequent extension trial. Maximum memantine doses were determined by body weight and ranged from 3 to 15 mg/day. RESULTS: There was one serious adverse event (SAE) (affective disorder, with memantine) in the 12 week study and one SAE (lobar pneumonia) in the 48 week extension; both were deemed unrelated to treatment. Other AEs were considered mild or moderate and most were deemed not related to treatment. No clinically significant changes occurred in clinical laboratory values, vital signs, or electrocardiogram (ECG). There was no significant between-group difference on the primary efficacy outcome of caregiver/parent ratings on the Social Responsiveness Scale (SRS), although an improvement over baseline at Week 12 was observed in both groups. A trend for improvement at the end of the 48 week extension was observed. No improvements in the active group were observed on any of the secondary end-points, with one communication measure showing significant worsening with memantine compared with placebo (p = 0.02) after 12 weeks. CONCLUSIONS: This trial did not demonstrate clinical efficacy of memantine ER in autism; however, the tolerability and safety data were reassuring. Our results could inform future trial design in this population and may facilitate the investigation of memantine ER for other clinical applications.
21
Catherine Lord, Michael Rutter, Ann Le Couteur · Journal of Autism and Developmental Disorders · 1994 · 9.1K citations
Education, Psychiatry, Psychology +13
Risperidone in Children with Autism and Serious Behavioral Problems
James T. McCracken, James J. McGough, Bhavik Shah et al. · New England Journal of Medicine · 2002 · 1.6K citations · Full text
Postmortem brain abnormalities of the glutamate neurotransmitter system in autism
Amy E. Purcell, Ok Hee Jeon, Andrew W. Zimmerman et al. · Neurology · 2001 · 505 citations